Foresite Capital — 2021 Investments
6 investments dated 2021 · listed companies and verified rows first · show all
BiotechLondon
James Ede-Golightly(Director)Alistair Gray(Director)Craig Tooman(Executive Officer)Dave Lemus(Director)Giles Campion(Executive Officer)Romano Steven(Director)
Co-investorsMC Healthcare VenturesNextech InvestVivo Capital
HealthtechSan Francisco, US
June Lee(Executive Officer, Director)
BoardJames Tananbaum(Director)
Board seatMichael RomeVikram Bajaj· per SEC Form D · $60M raise · filed Mar 2021
Co-investorsSamsara BioCapital
HealthtechSouth San Francisco, US
Zachary Sweeney(Executive Officer, Director)
Board seatJames TananbaumVikram Bajaj· per SEC Form D · $50M raise · filed Nov 2021
Pardes Biosciences develops oral medications designed to treat and prevent viral infections, including COVID-19.
BiotechHealthtechSan Francisco, US
Uri Lopatin(Founder/CEO)inUri A. Loptain(Executive Officer, Director)Heidi Henson(Executive Officer)Elizabeth Lacy(Executive Officer)Lee Arnold(Executive Officer)
BoardJ. Jay Lobell(Director)
Board seatJames B. Tananbaum· per SEC Form D
Co-investorsY CombinatorKhosla Ventures
Kriya Therapeutics is a biopharmaceutical company that develops and manufactures one-time gene therapies aimed at treating prevalent chronic diseases.
BiotechHealthtechMorrisville, US
Shankar Ramaswamy(Co-Founder, Chairman & CEO)Roger Jeffs(Co-Founder & Vice Chairman)Fraser Wright(Scientific Co-Founder & Chief Gene Therapy Officer)Shankar Ramaswamy, M.D.(Founder)inMichele Stone(Chief Scientific Officer)Katherine Eade(Chief Legal Officer)
Co-investorsPatient Square CapitalPremji InvestAmplo VenturesBluebird VenturesJDRF T1D FundNarya Capital+2 more
Cambridge, MA biotech developing single-course in vivo base editing medicines to permanently lower cardiovascular disease risk.
BiotechCambridge, US
Andrew Ashe(Executive Officer)Sekar Kathiresan(Executive Officer, Director)Andrew Bellinger(Executive Officer)
BoardJohn Evans(Director)Anthony Philippakis(Director)inKrishna Yeshwant(Director)in
Co-investorsARCH Venture PartnersF-Prime CapitalGV (Google Ventures)RA CapitalvenBio Partners
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.